Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.
Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Xu M, et al. Among authors: tapia c. J Immunother Precis Oncol. 2021 May 14;4(2):45-52. doi: 10.36401/JIPO-21-5. eCollection 2021 May. J Immunother Precis Oncol. 2021. PMID: 35663531 Free PMC article.
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Habra MA, et al. Among authors: tapia c. J Immunother Cancer. 2019 Sep 18;7(1):253. doi: 10.1186/s40425-019-0722-x. J Immunother Cancer. 2019. PMID: 31533818 Free PMC article. Clinical Trial.
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Naing A, et al. Among authors: tapia c. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347. J Immunother Cancer. 2020. PMID: 32188704 Free PMC article. Clinical Trial.
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.
Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Tapia C, et al. J Immunother Cancer. 2020 Apr;8(1):e000665. doi: 10.1136/jitc-2020-000665. J Immunother Cancer. 2020. PMID: 32303619 Free PMC article. Clinical Trial.
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Meric-Bernstam F, et al. Among authors: tapia c. JCO Precis Oncol. 2018;2018:PO.17.00245. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25. JCO Precis Oncol. 2018. PMID: 30035249 Free PMC article.
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. Owusu-Brackett N, et al. Among authors: tapia c. Oncotarget. 2019 Aug 20;10(49):5011-5019. doi: 10.18632/oncotarget.27082. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489111 Free PMC article.
Molecular determinants of post-mastectomy breast cancer recurrence.
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Keene KS, et al. Among authors: tapia c. NPJ Breast Cancer. 2018 Oct 12;4:34. doi: 10.1038/s41523-018-0089-z. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30345349 Free PMC article.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. Evans KW, et al. Among authors: tapia c. Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615. Clin Cancer Res. 2017. PMID: 29093017 Free PMC article.
249 results